Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew launches orthobiologics spinout. CMS proposes CED for wound care gel. More news briefs.

You may also be interested in...



New Products In Brief

Recent approvals and launches include Abbott’s Omnilink Elite balloon expandable vascular stent for iliac artery disease and J&J/Codman’s Medstream implantable infusion pump for spasticity.

CMS In Brief

Medicare advisors to meet on ventricular assist devices. CMS decides on coverage-with-evidence development for platelet-rich plasma wound care gel. More news from the Medicare agency.

Wound Therapy Firm Pushes For More Flexibility In Coverage-With-Evidence Conditions

CMS recently proposed to lift a long-established non-coverage policy for platelet-rich plasma wound therapy, but only for patients enrolled in a randomized trial. Manufacturer Cytomedix says a registry-based observational study would be a better approach.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT031220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel